title: Predicting prostate specific antigen failure after radical retropubic prostatectomy for T1c prostate cancer.
abstract: OBJECTIVE
  Clinicopathological data were reviewed to find a predictor of prostate specific antigen (PSA) failure in Taiwanese patients who had received radical retropubic prostatectomy (RRP) for stage T1c prostate cancer (PC).
  
  
  METHODS
  Fifty-five consecutive men who underwent RRP for stage T1c PC were included. The clinical end point was PSA failure (PSA >0.2 ng/ml). Preoperative PSA, free-to-total PSA ratio, prostate volume, PSA density, transrectal sextant biopsy and whole mount of RRP parameters were analyzed for their ability to predict postoperative PSA failure.
  
  
  RESULTS
  Fifteen of the 55 patients developed PSA failure during the follow-up period. Those with PSA failure had higher PSA, higher percentage of cancer in biopsies and higher biopsy Gleason score than the freedom from PSA failure group (all P < 0.05). The PSA failure group had higher pathology Gleason score and a higher incidence of extracapsular tumor extension than the freedom from PSA failure group (all P < 0.05). The PSA failure group had a larger tumor volume and higher incidence of combined peripheral lobe with transitional lobe involvement than the freedom from PSA failure group (all P < 0.05). Multivariate analysis revealed that the predictors for PSA failure after RRP were biopsy Gleason score > or =6, tumor volume > or =2.5 ml and PSA > or =10 ng/ml.
  
  
  CONCLUSIONS
  The single most significant predictor for PSA failure in T1c PC patients after RRP was tumor volume > or =2.5 ml.
authors.affiliation: Division of Urology, Department of Surgery, Taichung Veterans General Hospital, National Yang-Ming University School of Medicine, Taiwan.
authors.forename: Yen-Chuan
authors.initials: YC
authors.lastname: Ou
authors.forename: Jung-Ta
authors.initials: JT
authors.lastname: Chen
authors.forename: Chi-Rei
authors.initials: CR
authors.lastname: Yang
authors.forename: Chen-Li
authors.initials: CL
authors.lastname: Cheng
authors.forename: Hao-Chung
authors.initials: HC
authors.lastname: Ho
authors.forename: Jiunn-Liang
authors.initials: JL
authors.lastname: Ko
authors.forename: Yih-Shou
authors.initials: YS
authors.lastname: Hsieh
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D001706:Biopsy; D005544:Forecasting; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen